GC Wealth Management RIA LLC Has $4.05 Million Stock Position in Astrazeneca Plc $AZN

GC Wealth Management RIA LLC lessened its holdings in Astrazeneca Plc (NYSE:AZN) by 42.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,528 shares of the company’s stock after selling 14,873 shares during the quarter. GC Wealth Management RIA LLC’s holdings in Astrazeneca were worth $4,049,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. IHT Wealth Management LLC grew its position in Astrazeneca by 0.3% in the fourth quarter. IHT Wealth Management LLC now owns 17,527 shares of the company’s stock valued at $3,076,000 after purchasing an additional 54 shares in the last quarter. Visionary Wealth Advisors lifted its position in Astrazeneca by 1.5% during the 4th quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock worth $737,000 after buying an additional 60 shares in the last quarter. Vista Investment Management boosted its stake in shares of Astrazeneca by 0.3% during the 4th quarter. Vista Investment Management now owns 21,215 shares of the company’s stock worth $3,723,000 after buying an additional 60 shares during the last quarter. Kestra Investment Management LLC grew its holdings in shares of Astrazeneca by 1.9% in the 4th quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock valued at $595,000 after acquiring an additional 63 shares in the last quarter. Finally, Luken Investment Analytics LLC grew its holdings in shares of Astrazeneca by 4.3% in the 4th quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock valued at $274,000 after acquiring an additional 64 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

AZN has been the topic of a number of recent research reports. HSBC downgraded Astrazeneca from a “buy” rating to a “hold” rating in a research report on Monday, July 13th. Weiss Ratings downgraded Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 18th. Wall Street Zen upgraded Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. Finally, Barclays reissued a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $211.00.

Astrazeneca Price Performance

Shares of NYSE AZN opened at $168.41 on Friday. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The business’s 50 day moving average price is $180.80 and its two-hundred day moving average price is $188.05. The company has a market cap of $261.19 billion, a PE ratio of 25.29, a price-to-earnings-growth ratio of 1.38 and a beta of 0.24. Astrazeneca Plc has a twelve month low of $142.98 and a twelve month high of $212.71.

Astrazeneca (NYSE:AZN) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The company had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. On average, analysts predict that Astrazeneca Plc will post 10.22 EPS for the current year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.